Healthcare AI Equity: What the 2025-2026 Round Data Actually Says
Healthcare AI Equity: What the 2025-2026 Round Data Actually Says
Healthcare AI growth rounds priced at a median 8.4x forward revenue in H1 2026, down from 11.2x twelve months prior (PitchBook US Venture Deal Terms, Q2 2026). The headline compression hides a sharper split: clinical-workflow companies with contracted hospital revenue held multiples; horizontal copilots without enterprise traction lost roughly 40 percent of their 2024 pricing.
The pricing split is wider than the headline
Aggregate healthcare AI multiples tell one story; the underlying distribution tells a different one. PitchBook's Q2 2026 deal terms data shows the top quartile of healthcare AI growth rounds clearing at 14.1x forward revenue, while the bottom quartile cleared at 3.9x. That spread, roughly 10 turns of revenue between top and bottom, is the widest the sector has shown since 2021. In most growth-stage sectors, the top-to-bottom quartile spread sits closer to 4-5 turns.
What separates the quartiles is not model sophistication or team pedigree. It is contracted enterprise revenue. Carta's H1 2026 State of Private Markets read shows healthcare AI companies with 70 percent or more revenue from signed enterprise contracts (versus pilot or usage-based) priced at a median 11.8x. Companies with majority pilot or consumption revenue priced at 5.2x. The market has stopped paying for ARR that looks like ARR but behaves like services revenue.
Term structure is moving faster than price
Cooley GO's Q1 2026 Venture Financing Report flagged a 31 percent increase in healthcare AI rounds carrying participating preferred, up from 18 percent in Q1 2025. Liquidation preference multiples above 1.0x appeared in 22 percent of healthcare AI growth rounds in H1 2026, against 9 percent the prior year. These are not the kind of terms that show up when pricing is healthy. They show up when investors believe the asset class is mispriced but are willing to write the check on protected economics.
Across our advisory work with growth-stage healthcare AI founders in 2025-2026, we observe a consistent pattern in the term sheets founders bring us for second opinions. The headline valuation is roughly in line with the PitchBook median. The structure underneath, participation, multiple liquidation preferences, ratchets tied to clinical milestones, costs the founder 5-7 points of effective dilution at exit beyond what the cap table shows. Founders pricing only on the pre-money number are losing the round before they sign it.
Where capital is concentrating
NVCA's 2026 mid-year yearbook update tracks healthcare AI investment by sub-vertical. Clinical decision support and revenue cycle automation captured 58 percent of 2026 H1 healthcare AI growth capital, against 34 percent in 2024. Patient-facing chatbots, ambient scribing for general practice, and consumer health LLMs collectively captured 11 percent in H1 2026, against 29 percent two years prior. Bloomberg ECM data shows the two healthcare AI IPOs filed in 2026 both operate in clinical workflow categories, neither in consumer-facing.
The capital concentration tracks the regulatory and reimbursement environment. CMS finalized two AI-specific CPT codes in Q4 2025 covering clinical decision support in radiology and pathology. Companies positioned against those reimbursement codes are pricing on reimbursable revenue, which institutional investors value differently from pilot ARR. Companies without a reimbursement path or a signed health-system contract are priced on user growth, and user growth has lost its premium.
What this means for founders 90 days from a round
The 8.4x median is a misleading anchor. Founders preparing a growth round in the next two quarters should run two parallel pricing exercises: one against the headline median, one against the quartile their revenue mix actually places them in. The gap between the two is usually 4-6 turns of revenue, which translates to 30-50 percent of the round size at the same dilution.
Yanne Capital is an independent boutique investment bank advising growth-stage companies on equity, debt, and M&A transactions across 26 sectors, with 240+ closed deals and relationships with 3,500+ institutional investors globally. We are your trusted filter between noise and signal. Healthcare AI has been a heavy weight in our 2025-2026 advisory book, and the founders who price accurately against contracted revenue, rather than pilot ARR, close on cleaner structure 4-6 weeks faster than the founders who anchor on the headline multiple.
If you are 90 days from a healthcare AI growth round, reach out at contact@yannecapital.com for a second read on your pricing and term sheet against the H1 2026 quartile distribution.
